Overview

Drug Eluting Stents Market is poised to value over USD 3.9 billion by 2027 end at a CAGR of over 6.4% during the forecast period 2020 to 2027.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Drug Eluting Stents Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Drug Eluting Stents Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Rising geriatric population, unhealthy food habits, sedentary lifestyle and a lack of exercise are some of the key factors driving the drug eluting stents market growth. Additionally, the drastic shift to DES from angioplasty for treating atherosclerosis across the world has significantly boosted the market growth. Furthermore, the DS technique is minimally invasive which shall propel the proliferation of the market. On the other hand, the risks in implementing DES technique such as endothelial tissues regrowth disruption and stent thrombosis shall restrain the proliferation of the market. 

Major players included in the Drug Eluting Stents Market:
• Boston Scientific Corporation
• Medtronic, Plc.
• Abbott Laboratories
• Biosensors International Group
• Biotronik
• Lepu Medical Technology
• Terumo Medical Corporation
• Cook Medical
• Shandong JW Medical Systems
• Stentys
• Abbott Vascular Inc.
• AlviMedica Medical Technologies Inc.
• Amaranth Medical, Inc.
• HangZhou HuaAn Biotechnology Co.,Ltd
• Xtent, Inc.
• Cardionovum GmbH
• Cordis Corporation
• Kyoto Medical Planning Co., Ltd.
(Note: The list of the major players will be updated with the latest market scenario and trends)

Drug Eluting Stents Market Segmentation:

By Drug
• Sirolimus
• Paclitaxel
• Zotarolimus 
• Everolimus
• Biolimus 
• Others

By Coating Type
• Polymer-based Coatings
• Polymer-free Coatings

By Application
• Coronary Artery Disease
• Peripheral Artery Disease

By End User
• Cardiology Centers
• Ambulatory Surgery Centers (ASCs)
• Hospitals

By Region
•    North America
•    Europe
•    Asia-Pacific
•    Latin America
•    Middle East and Africa

Regional Analysis:

The North America region expected to dominate the global market, and this can be credited to stringencies in guidelines for medical device approval and manufacturing. Additionally, improved reimbursement coverage along with high rate of incidence of artery diseases has bolstered the proliferation of the market. 

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
•    Growth prospects
•    SWOT analysis 
•    Key market trends 
•    Key data-points affecting market growth

Objectives of the Study:
•    To provide with an exhaustive analysis on the global drug eluting stents market By Drug, By Coating Type, By Application, By End User and by region
•    To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
•    To evaluate and forecast micro-markets and the overall market 
•    To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
•    To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:
•    We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
•    The customization Mobility Care offered are free of charge with purchase of any license of the report
•    You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
   1.1. Objectives of the Study 
   1.2. Market Definition 
   1.3. Market Scope 
        1.3.1. Years Considered for the Study
        1.3.2. Market Covered
   1.4. Currency 
   1.5. Limitations 
   1.6. Stakeholders 

2. Research Methodology 
   2.1. Research Data 
        2.1.1. Secondary Data
               2.1.1.1. Key Data from Secondary Sources
        2.1.2. Primary Data
               2.1.2.1. Key Data from Primary Sources
   2.2. Market Size Estimation 
   2.3. Market Breakdown and Data Triangulation 
   2.4. Assumptions for the Study  

3. Executive Summary
   3.1. Market Outlook
   3.2. Segment Outlook
   3.3. Competitive Insights

4. Global Drug Eluting Stents Market Variables, Trends & Scope
   4.1. Market Lineage Outlook
   4.2. Penetration and Growth Prospect Mapping
   4.3. Industry Value Chain Analysis
   4.4. Cost Analysis Breakdown
   4.5. Technology Overview
   4.6. Regulatory Framework
        4.6.1. Reimbursement Framework
        4.6.2. Standards and Compliances

5. Market Overview
   5.1. Market Dynamics
        5.1.1. Market Driver Analysis
               5.1.1.1. Increasing focus of Drug Eluting Stents Market Companies on Brand Protection
               5.1.1.2. Untapped Opportunities in Emerging Regions
        5.1.2. Market Restraint Analysis
               5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
        5.1.3. Industry Challenges
               5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Global Drug Eluting Stents Market Analysis Tools
   6.1. Industry Analysis - Porter’s
        6.1.1. Supplier Power
        6.1.2. Buyer Power
        6.1.3. Substitution Threat
        6.1.4. Threat from New Entrants
        6.1.5. Competitive Rivalry
   6.2. Pestel Analysis
        6.2.1. Political Landscape
        6.2.2. Environmental Landscape
        6.2.3. Social Landscape
        6.2.4. Technology Landscape
        6.2.5. Legal Landscape
   6.3. Major Deals And Strategic Alliances Analysis
        6.3.1. Joint Ventures
        6.3.2. Mergers and Acquisitions
        6.3.3. Licensing and Partnership
        6.3.4. Technology Collaborations
        6.3.5. Strategic Divestments
   6.4. Market Entry Strategies
   6.5. Case Studies

7. Global Drug Eluting Stents Market, By Drug Historical Analysis and Forecast 2020-2027 (USD Million)
   7.1. Sirolimus
   7.2. Paclitaxel
   7.3. Zotarolimus 
   7.4. Everolimus
   7.5. Biolimus 
   7.6. Others

8. Global Drug Eluting Stents Market, By Coating TypeHistorical Analysis and Forecast 2020-2027 (USD Million)  
   8.1. Polymer-based Coatings
   8.2. Polymer-free Coatings

9. Global Drug Eluting Stents Market, By Application Historical Analysis and Forecast 2020-2027 (USD Million)  
   9.1. Coronary Artery Disease
   9.2. Peripheral Artery Disease

10. Global Drug Eluting Stents Market, By End User Historical Analysis and Forecast 2020-2027 (USD Million)  
    10.1. Cardiology Centers
    10.2. Ambulatory Surgery Centers (ASCs)
    10.3. Hospitals

11. North America Drug Eluting Stents Market Analysis 2015-2019 and Forecast 2020–2027 (USD Million)
    11.1. Introduction
    11.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
          11.2.1. U.S.A
          11.2.2. Canada
          11.2.3. Mexico
    11.3. Market Size (USD Million) Forecast for North America 2020-2027

12. Latin America Drug Eluting Stents Market Analysis 2015-2019 and Forecast 2020–2027 (USD Million)
    12.1. Introduction
    12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
          12.2.1. Brazil
          12.2.2. Venezuela
          12.2.3. Argentina
          12.2.4. Rest of Latin America
    12.3. Market Size (USD Million) Forecast for Latin America 2020-2027

13. Europe Drug Eluting Stents Market Analysis 2015-2019 and Forecast 2020–2027 (USD Million)
    13.1. Introduction
    13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
          13.2.1. Germany
          13.2.2. U.K         
          13.2.3. France
          13.2.4. Italy
          13.2.5. Spain
          13.2.6. Russia
          13.2.7. Poland
          13.2.8. Rest of Europe
    13.3. Market Size (USD Million) Forecast for Europe 2020-2027

14. Asia Pacific Drug Eluting Stents Market Analysis 2015-2019 and Forecast 2020–2027 (USD Million)
    14.1. Introduction
    14.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
          14.2.1. Japan
          14.2.2. China
          14.2.3. India
          14.2.4. Australia and New Zealand
          14.2.5. ASEAN
          14.2.6. Rest of Asia Pacific
    14.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027  

15. Middle East and Africa Market Analysis 2015-2019 and Forecast 2020–2027 (USD Million)
    15.1. Introduction
    15.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
          15.2.1. Saudi Arabia
          15.2.2. UAE
          15.2.3. South Africa
          15.2.4. Egypt
    15.3. Market Size (USD Million) Forecast for MEA 2020-2027

16. Market Share Analysis and Competitive Landscape   
    16.1. Global Landscape - Key Players, Revenue and Presence
    16.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
    16.3. Global Emerging Companies
    16.4. North America - Market Share Analysis and Key Regional Players
    16.5. Europe - Market Share Analysis and Key Regional Players
    16.6. Asia Pacific - Market Share Analysis and Key Regional Players
    16.7. Global Key Player - Growth Matrix

17. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    17.1. Boston Scientific Corporation
          17.1.1. Company Overview
          17.1.2. Product Portfolio
          17.1.3. SWOT Analysis
          17.1.4. Financial Overview
          17.1.5. Strategic Overview
    17.2. Medtronic, Plc.
          17.2.1. Company Overview
          17.2.2. Product Portfolio
          17.2.3. SWOT Analysis
          17.2.4. Financial Overview
          17.2.5. Strategic Overview 
    17.3. Abbott Laboratories
          17.3.1. Company Overview
          17.3.2. Product Portfolio
          17.3.3. SWOT Analysis
          17.3.4. Financial Overview
          17.3.5. Strategic Overview
    17.4. Biosensors International Group
          17.4.1. Company Overview
          17.4.2. Product Portfolio
          17.4.3. SWOT Analysis
          17.4.4. Financial Overview
          17.4.5. Strategic Overview
    17.5. Biotronik
          17.5.1. Company Overview
          17.5.2. Product Portfolio
          17.5.3. SWOT Analysis
          17.5.4. Financial Overview
          17.5.5. Strategic Overview          
    17.6. Lepu Medical Technology
          17.6.1. Company Overview
          17.6.2. Product Portfolio
          17.6.3. SWOT Analysis
          17.6.4. Financial Overview
          17.6.5. Strategic Overview      
    17.7. Terumo Medical Corporation
          17.7.1. Company Overview
          17.7.2. Product Portfolio
          17.7.3. SWOT Analysis
          17.7.4. Financial Overview
          17.7.5. Strategic Overview
    17.8. Cook Medical
          17.8.1. Company Overview
          17.8.2. Product Portfolio
          17.8.3. SWOT Analysis
          17.8.4. Financial Overview
          17.8.5. Strategic Overview 
    17.9. Shandong JW Medical Systems
          17.9.1. Company Overview
          17.9.2. Product Portfolio
          17.9.3. SWOT Analysis
          17.9.4. Financial Overview
          17.9.5. Strategic Overview 
    17.10. Stentys
          17.10.1. Company Overview
          17.10.2. Product Portfolio
          17.10.3. SWOT Analysis
          17.10.4. Financial Overview
          17.10.5. Strategic Overview
    17.11. Abbott Vascular Inc.
          17.11.1. Company Overview
          17.11.2. Product Portfolio
          17.11.3. SWOT Analysis
          17.11.4. Financial Overview
          17.11.5. Strategic Overview          
    17.12. AlviMedica Medical Technologies Inc.
          17.12.1. Company Overview
          17.12.2. Product Portfolio
          17.12.3. SWOT Analysis
          17.12.4. Financial Overview
          17.12.5. Strategic Overview      
    17.13. Amaranth Medical, Inc
          17.13.1. Company Overview
          17.13.2. Product Portfolio
          17.13.3. SWOT Analysis
          17.13.4. Financial Overview
          17.13.5. Strategic Overview
    17.14. HangZhou HuaAn Biotechnology Co.,Ltd
          17.14.1. Company Overview
          17.14.2. Product Portfolio
          17.14.3. SWOT Analysis
          17.14.4. Financial Overview
          17.14.5. Strategic Overview 
    17.15. Xtent, Inc.
          17.15.1. Company Overview
          17.15.2. Product Portfolio
          17.15.3. SWOT Analysis
          17.15.4. Financial Overview
          17.15.5. Strategic Overview 
    17.16. Cardionovum GmbH
          17.16.1. Company Overview
          17.16.2. Product Portfolio
          17.16.3. SWOT Analysis
          17.16.4. Financial Overview
          17.16.5. Strategic Overview
    17.17. Cordis Corporation
          17.17.1. Company Overview
          17.17.2. Product Portfolio
          17.17.3. SWOT Analysis
          17.17.4. Financial Overview
          17.17.5. Strategic Overview 
    17.18. Kyoto Medical Planning Co., Ltd.
          17.18.1. Company Overview
          17.18.2. Product Portfolio
          17.18.3. SWOT Analysis
          17.18.4. Financial Overview
          17.18.5. Strategic Overview

18. Pre and Post COVID-19 Impact
    18.1. Positive influence on the healthcare industry
    18.2. The financial disruption of the manufacturing sector
    18.3. Impact of COVID-19 on emerging companies
    18.4. Significant mandates in the healthcare regulations initiated by administrations
    18.5. The overall economic slowdown of the developing and developed nations

19. FutureWise SME Key Takeaway Points for Client
 

Tables

Figures